Synonym: N9-(3-(Dimethylamino)propyl)-N3,N3,N6,N6-tetramethylacridine-3,6,9-triamine hydrochloride
Empirical Formula (Hill Notation): C22H32N5 · xHCl
Molecular Weight: 366.52 (free base basis)
Linear Formula: C22H32N5 · xHCl
Product Type: Chemical
assay |
≥98% (HPLC) |
color |
yellow to orange |
form |
powder |
Quality Level |
100 ![External link](https://krackeler.com/images/sigma/ext-link.gif) |
SMILES string |
CN(C)CCCNC1=C2C(C=C(N(C)C)C=C2)=NC3=C1C=CC(N(C)C)=C3 |
solubility |
DMSO: 25 mg/mL, clear |
storage condition |
desiccated |
storage temp. |
2-8°C |
Biochem/physiol Actions: |
3,6-DMAD is also called as N9-(3-(dimethylamino)propyl)-N3,N3,N6,N6-tetramethylacridine-3,6,9-triamine. It prevents the development of multiple myeloma (MM) tumor xenografts. |
Biochem/physiol Actions: |
3,6-DMAD is an acridine derivative that selectively suppresses ER stress- (300 nM Thapsigargin) induced HT1080 cellular XBP1 mRNA splicing (Eff. conc. 500 nM), but not eIF2a phosphorylation, by directly inhibiting IRE1? RNase (endoribonuclease) activity and disrupting IRE1α oligomerization. 3,6-DMAD is shown to exhibit anti-multiple myeloma efficacy in cultures in vitro (%survival/[3,6-DMAD]/cell line/24 h = 13%/4 M/RPMI 8226 and 8%/1 μM/MM1.R) and completely suppress the expansion of established RPMI 8226 tumor in mice in vivo when administered via intraperitoneal injection (10 mg/kg q.o.d.). |
Packaging: |
5, 25 mg in glass bottle |
RIDADR |
NONH for all modes of transport |
WGK Germany |
WGK 3 |
Flash Point(F) |
Not applicable |
Flash Point(C) |
Not applicable |
Purity |
≥98% (HPLC) |
Storage Temp. |
2-8°C |
UNSPSC |
12352200 |